Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations
about
A case of cryopyrin-associated periodic syndrome with kidney transplant failure.Whole genome sequencing identifies missense mutation in MTBP in Shar-Pei affected with Autoinflammatory Disease (SPAID)Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1β.A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.NLRs in immune privileged sitesAn expanding role for interleukin-1 blockade from gout to cancer.Autoinflammation: translating mechanism to therapy.Nod-like receptor protein-3 inflammasome plays an important role during early stages of wound healing.Therapy of autoinflammatory syndromes.Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal studyUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Cryopyrin-associated periodic syndromes and autoinflammation.Biological treatments: new weapons in the management of monogenic autoinflammatory disordersThe NOD2 defect in Blau syndrome does not result in excess interleukin-1 activityDevelopments in the scientific and clinical understanding of autoinflammatory disordersTreating inflammation by blocking interleukin-1 in humans.Cryopyrin-associated periodic syndromes: background and therapeutics.Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response.The emerging role of interleukin-1β in autoinflammatory diseases.Clinical immunology review series: An approach to the patient with a periodic fever syndrome.Unexplained recurrent fever: when is autoinflammation the explanation?Anakinra for cryopyrin-associated periodic syndrome.Urticaria mimickers in children.Monogenic autoinflammatory diseases.Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.Pharmacological treatment options for cryopyrin-associated periodic syndromes.Inflammasomes and dermatology.Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes.The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases.Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature.Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1β and rapid response to anakinra.Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.Cryopyrin-associated periodic syndrome.[Autoinflammatory syndromes/fever syndromes].Successful renal transplantation in Muckle-Wells syndrome treated with anti-IL-1β-monoclonal antibody.Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS).Identification of Interleukin-1β-Producing Monocytes That Are Susceptible to Pyronecrotic Cell Death in Patients With Neonatal-Onset Multisystem Inflammatory Disease.Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.
P2860
Q33622218-B9BAF30F-0A73-4153-BEA8-D77577023195Q33640755-5F250F10-E0C4-47FE-9C0E-470929C42B4FQ34504994-041AA318-F045-4A85-82E4-03B98F4D1C9AQ34632661-3C437198-F397-426E-A46C-5E127E7406CAQ35169896-E5939D70-8E8D-4C81-A9F2-39D829D715E6Q35219001-FF3A399B-B762-4765-A33A-9B3CF28FB03AQ35558406-9A32E5F6-97A5-446C-9304-A2EDF9D5E6CFQ35582494-E67E5BE8-EA13-43D3-A9C6-60F6D309A20DQ35868028-8470FAF8-AD7A-44AD-9A8E-D002DCB67F1EQ35907804-FF4F77A1-21E8-4E31-A7F3-F1116D90A77CQ36171750-464A283C-3165-4664-AE26-81C09B0AD269Q36967373-A1D6741B-E903-4A6D-A84D-0F6871A3F080Q37077564-8F689E17-820C-4460-B818-DC9257404F02Q37124443-F84A582F-4449-4535-8C68-99356E6B9052Q37207033-7850D26D-3F75-444E-ABAF-96A9CB3B8916Q37636664-3D385B6E-52C3-44EC-AEAB-A9F307C6EDE1Q37688957-C91C4589-8CC8-4E2A-811E-0488DE07C840Q37811988-371D9D2E-41F1-4E51-AEAD-A0FC319C24E6Q37897494-12F8C071-53C8-4777-BA96-9649CB1C4F50Q37898725-D214F993-18D6-44B0-B8B2-E995FF66C697Q38075002-760D511A-8452-4724-B32B-003716DFBECAQ38168948-07522FF0-A5E8-4DFA-BB14-A11432BAD9C4Q38189469-AEF51553-B798-4B42-9E35-A6439DB856C7Q38211947-0947B7DD-CB5B-4898-8702-6E87BB98F82DQ38574807-07856DDF-4986-46EC-A83A-1FA70310283CQ38674213-D03C4D5F-AA91-4739-94A8-ECA5EC56D770Q38797090-1B439668-EC15-411E-BE1F-BAF3EBC0AA76Q38993312-37CB97D0-0FFB-4D83-88F8-E39360392207Q39132605-E19C41FC-8E3B-4F19-BE74-7E2935D19398Q39377061-6E4D3FF6-9A7E-41A4-AC62-683D7DF018A2Q39377686-DCC63BE3-3234-4E44-A807-B32E3F84A30CQ40100395-73C4E954-24FF-41CF-B10B-E908A9784647Q40277625-D92A6CCC-6C4F-4B76-A442-DFCBA5542AF0Q40326095-9F36E27E-27F4-47E8-974D-7ED7F282FA9CQ40338012-B9C98619-A135-42E5-83C1-E0551E1D4644Q40356964-F7346F1B-8035-4060-B544-F8CE9C032BDEQ41493529-FA844E24-784C-4FFC-AFD5-6D21AB98A98CQ42032205-F56ACB1B-EAEE-4861-9904-75AD1F65B59EQ45325652-0A57F7BB-F408-49DC-AB1B-446CC5AABABAQ50434769-E1DFC0FC-79F7-4E68-9061-5CFE61F988AF
P2860
Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@ast
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@en
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@en-gb
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@nl
type
label
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@ast
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@en
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@en-gb
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@nl
prefLabel
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@ast
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@en
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@en-gb
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@nl
P2093
P921
P3181
P1433
P1476
Phenotype, genotype, and susta ...... ed with CIAS-1/NALP3 mutations
@en
P2093
Alison Bybee
Clive E Grattan
Elizabeth Bruning
J Ruth Gallimore
Kieron S Leslie
Patricia Woo
Philip F Roberts
Philip N Hawkins
P304
P3181
P356
10.1001/ARCHDERM.142.12.1591
P407
P577
2006-12-01T00:00:00Z